InxMed
China - Beijing
BiotechnologyFocus: Oncology Treatments
InxMed is a life sciences company focused on Oncology Treatments.
Oncology
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
4
Pipeline & Clinical Trials
IN10018
Gastric CancerClinical Trials (1)
NCT05327231IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
Phase 1IN10018
Metastatic MelanomaClinical Trials (1)
NCT04109456IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
Phase 1IN10018+PLD
Locally Advanced or Metastatic Solid TumorsClinical Trials (1)
NCT05830539IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
Phase 1/2IN10018
Pancreatic CancerClinical Trials (1)
NCT05827796IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Phase 1/2IN10018 in combination with RNK08954
Solid Tumor CancerClinical Trials (1)
NCT07441174IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
Phase 1/2D-1553
Solid TumorClinical Trials (1)
NCT05379946Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
Phase 1/2D1553
Solid TumorClinical Trials (1)
NCT06166836a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
Phase 1/2IN10018
Solid TumorClinical Trials (1)
NCT05982522IN10018 Combination Therapy in Previously-treated Solid Tumors
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT06030258IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Phase 1/2IN10018 in combination with PLD
Platinum-resistant Ovarian CancerClinical Trials (1)
NCT05551507IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
Phase 1/2IN10018
NSCLCClinical Trials (1)
NCT05994131IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Phase 1/2IN10018
Ovarian Cancer RecurrentClinical Trials (1)
NCT06014528IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Phase 2IN10018 in combination with D-1553
Non-Small Cell Lung CancerClinical Trials (1)
NCT07174908A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Phase 3Open Jobs (4)
Interview Prep Quick Facts
Founded: 2018
Portfolio: 13 clinical trials
Top TAs: Oncology
Publications: 11 in PubMed
Open Roles: 4 active jobs